DepoMed, Inc. is a specialty pharmaceutical company focused on developing and commercializing products to treat pain and other central nervous system conditions. In a transformative transaction, the company agreed to acquire the U.S. rights to NUCYNTA, a drug for severe pain, from Janssen Pharmaceuticals for $1.05 billion.

To finance the purchase, Deerfield and Pharmakon structured a flexible 7 year debt facility. The total facility was $575 million of which Deerfield provided $375 million.